Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial

Jonathan Corren, Pascal Chanez, Mario Castro, Leonardo Fabbri, Vijay N. Joish, Robert E. Evans, Neil M.H. Graham, Vera Mastey, Sara Villeneuve, Gaëlle Bégo-Le Bagousse, Christine Taniou, Puneet Mahajan, Ariel Teper, Gianluca Pirozzi, Laurent Eckert
European Respiratory Journal 2016 48: PA1530; DOI: 10.1183/13993003.congress-2016.PA1530

Article Information

vol. 48 no. suppl 60
DOI 
https://doi.org/10.1183/13993003.congress-2016.PA1530
Published By 
European Respiratory Society
Print ISSN 
0903-1936
Online ISSN 
1399-3003
History 
  • Published online November 8, 2016.
Copyright & Usage 
Copyright ©the authors 2016

Author Information

  1. Jonathan Corren1,
  2. Pascal Chanez2,
  3. Mario Castro3,
  4. Leonardo Fabbri4,
  5. Vijay N. Joish5,
  6. Robert E. Evans6,
  7. Neil M.H. Graham7,
  8. Vera Mastey5,
  9. Sara Villeneuve8,
  10. Gaëlle Bégo-Le Bagousse9,
  11. Christine Taniou10,
  12. Puneet Mahajan11,
  13. Ariel Teper12,
  14. Gianluca Pirozzi12 and
  15. Laurent Eckert13
  1. 1Medicine, Allergy & Immunology, David Geffen School of Medicine at UCLA, Los Angeles, United States
  2. 2U1067 INSERM Respiratory, Aix-Marseille Université, Marseille, France
  3. 3Department of Medicine, Washington University School of Medicine, Saint Louis, United States
  4. 4Department of Medicine, NOCSAE, University of Modena and Reggio Emilia, Modena, Italy
  5. 5Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Inc., Tarrytown, United States
  6. 6Clinical Sciences, Regeneron Pharmaceuticals, Inc., Tarrytown, United States
  7. 7Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, United States
  8. 8Stats, Ividata, Levallois-Perret, France
  9. 9Global Health Economics and Outcomes Research, Sanofi R&D, Chilly Mazarin, France
  10. 10BU Pharma and Industry, Experis-IT, Nanterre, France
  11. 11Global Health Economics and Outcomes Research, Sanofi R&D, Bridgewater, United States
  12. 12Research and Development, Sanofi R&D, Bridgewater, United States
  13. 13Global Health Economics and Outcomes Research, Sanofi R&D, Chilly Mazarin, France

Article usage

Article usage: November 2016 to August 2023

AbstractFullPdf
Nov 20163500
Dec 20163400
Jan 20174200
Feb 20171600
Mar 20175900
Apr 20173100
May 20172300
Jun 20171300
Jul 20172500
Aug 20174300
Sep 20173100
Oct 20172000
Nov 2017900
Dec 20173400
Jan 20183600
Feb 20182500
Mar 20182100
Apr 20182100
May 20181500
Jun 20181900
Jul 2018700
Aug 20184000
Sep 20183100
Oct 2018900
Nov 20182300
Dec 20181000
Jan 20191000
Feb 20193200
Mar 2019300
Apr 2019800
May 20191000
Jun 20191300
Jul 20192000
Aug 2019900
Sep 2019600
Oct 2019500
Nov 20191000
Dec 20192800
Jan 20206200
Feb 2020800
Mar 20201400
Apr 20202500
May 20201600
Jun 20201700
Jul 20201800
Aug 2020700
Sep 20201800
Oct 20203000
Nov 20202200
Dec 20201900
Jan 2021500
Feb 20211200
Mar 2021800
Apr 2021500
May 20212000
Jun 2021800
Jul 20211300
Aug 20211000
Sep 20211500
Oct 2021700
Nov 20211600
Dec 20211000
Jan 20227300
Feb 20223100
Mar 2022800
Apr 20221700
May 2022200
Jun 20221000
Jul 2022500
Aug 2022900
Sep 2022500
Oct 20221200
Nov 20221100
Dec 2022200
Jan 2023500
Feb 2023700
Mar 2023500
Apr 2023400
May 2023500
Jun 2023700
Jul 2023300
Aug 2023500

Altmetrics

Back to top
Email
Citation Tools

Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial
Jonathan Corren, Pascal Chanez, Mario Castro, Leonardo Fabbri, Vijay N. Joish, Robert E. Evans, Neil M.H. Graham, Vera Mastey, Sara Villeneuve, Gaëlle Bégo-Le Bagousse, Christine Taniou, Puneet Mahajan, Ariel Teper, Gianluca Pirozzi, Laurent Eckert
European Respiratory Journal Sep 2016, 48 (suppl 60) PA1530; DOI: 10.1183/13993003.congress-2016.PA1530
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To